Q4 2020 Alligator Bioscience AB Earnings Call Transcript
© -
Okay, thanks so much for the introduction. And I would like to welcome you all to this conference call, which will focus on our year-end report. Let's move to next slide, slide 2.
This is just to confirm, as usual the presentation does include some forward-looking statements.
With that, we go to the next slide, slide 3. So let's start with the agenda. I and Marie, will present with fourth quarter and year-end results 2020. We will also give a short pipeline updates and some outlooks for 2021. So the presentation will then be ended with a Q&A session. And with that, we can move to slide 4.
This is a summary of the key highlights in 2020. During the year, Alligator's increased our focus on clinical development, and to reach major clinical inflection points with selective programs. Our focus programs are ATOR-1017 and mitazalimab.
The decision to focus on ATOR-1017 and mita is based on their strong positioning. The positive data that supports a very competitive profile for the respective programs versus
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |